-
Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
Thursday, August 4, 2011 - 7:58am | 153Palatin Technologies, Inc. (NYSE: PTN) confirmed today the commencement of a Phase 1 clinical trial of AZD2820, a subcutaneously-administered peptide melanocortin receptor partial agonist, under development as a single-agent therapy for the treatment of obesity. AZD2820 is a clinical candidate...
-
News Summary for August 4, 2011
Thursday, August 4, 2011 - 7:51am | 587This is your Benzinga news summary and traders' outlook for Thursday, August 4, 2011, covering headlines from overnight and Thursday's pre-market session. Today in domestic pre-market trading, U.S. equity futures are set for a weak morning as traders wait for the jobless claims data. At last check...
-
Benzinga's Top Downgrades
Thursday, August 4, 2011 - 7:45am | 123Dendreon Corporation (NASDAQ: DNDN) was downgraded by Robert W. Baird from "outperform" to "neutral." DNDN's shares closed at $35.84 yesterday. Dendreon's trailing-twelve-month operating margin is -443.81%. JP Morgan downgraded Entropic Communications Inc (NASDAQ: ENTR) from “overweight” to “...
-
Santarus and Pharming Announce Special Protocol Assessment Agreement with FDA for RHUCIN Phase III Clinical Study
Thursday, August 4, 2011 - 6:53am | 70Santarus, Inc. (NASDAQ: SNTS) and biotech company Pharming Group NV earlier today announced that they have reached agreement with the U.S. Food and Drug Administration on the design of a Phase III clinical study with the investigational drug RHUCIN® (recombinant human C1 inhibitor) under the...
-
Piper Jaffray Downgrades Allergan To Neutral, Lowers PT To $89
Thursday, August 4, 2011 - 6:40am | 27Piper Jaffray has downgraded Allergan (NYSE: AGN) from Overweight to Neutral and has lowered the price target from $91 to $89.
-
Jefferies Upgrades AstraZeneca To Hold
Thursday, August 4, 2011 - 6:07am | 19Jefferies & Company has upgraded AstraZeneca (NYSE: AZN) from Underperform to Hold.
-
Options Brief: Auxilium Pharmaceuticals
Wednesday, August 3, 2011 - 3:08pm | 96Shares of Auxilium Pharmaceuticals (NASDAQ: AUXL) are lower on the session by 3.73%, trading at $15.98. Overall call volume is now running at 38.01x the daily average, with 98% of all calls traded being purchases on the offer. 2,547 contracts have traded on the session so far. Auxilium...
-
Rodman & Renshaw Maintains SuperGen Market Outperform, $5 PT
Wednesday, August 3, 2011 - 2:57pm | 81Rodman & Renshaw maintained its SuperGen (SUPG) Market Outperform rating and $5 price target in a research report published today. In the report, Rodman & Renshaw states, "We believe that the combined companies' pipeline could be valued at par with the average of a comparable group of...
-
McNicoll, Lewis & Vlak Reiterates Vivus Buy, $16 PT
Wednesday, August 3, 2011 - 1:37pm | 113McNicoll, Lewis & Vlak reiterated its Vivus (NASDAQ: VVUS) Buy rating and $16 price target in a research report published today. In the report, McNicoll, Lewis & Vlak states, "Although FORTRESS will have a greater number of dyads (mother-infant pairs), it will be similar in methodology and...
-
Piper Jaffray Reiterates Neutral on Somaxon Pharmaceuticals, Reduces PT to $2
Wednesday, August 3, 2011 - 8:49am | 43Piper Jaffray reiterated its Neutral rating on Somaxon Pharmaceuticals (NASDAQ: SOMX). At the same time, the rating agency reduced its price target on the company's stock from $2.50 to $2. On Tuesday, SOMX closed the day at $1.51.
-
Piper Jaffray Lowers PT On Somaxon Pharmaceuticals To $2
Wednesday, August 3, 2011 - 8:10am | 27Piper Jaffray has lowered the price target on Somaxon Pharmaceuticals (NASDAQ: SOMX) from $2.50 to $2 and maintains its Neutral rating.
-
Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine
Wednesday, August 3, 2011 - 8:01am | 93Merck (NYSE: MRK), known outside the United States and Canada as MSD, and Serum Institute of India Limited, an Indian company, announced today an agreement to work together to develop and commercialize a pneumococcal conjugate vaccine for use in the emerging and developing world countries. It is...
-
Piper Jaffray Overweight On Akorn
Wednesday, August 3, 2011 - 7:42am | 166Piper Jaffray is out with a research report on Akorn, Inc. (NASDAQ: AKRX) and it has an Overweight rating and a $10 price target on shares. In a note to clients, Piper Jaffray writes, "Yesterday, Akorn reported 2Q11 GAAP diluted EPS of $0.17, with adjusted EPS of $0.08 well ahead of our estimate...
-
Citi Reiterates Buy and PT of $73 on Johnson & Johnson
Wednesday, August 3, 2011 - 6:32am | 57Citi reiterated its Buy rating on Johnson & Johnson (NYSE: JNJ). At the same time, the rating agency left its price target on the company's stock unchanged at $73. On JNJ lost 1.52% of its value to end the day at $63.43. Its shares rebounded in today's pre-market trading, rising 0.36% to stand...
-
Stocks to Watch for Wednesday 8/03/2011: Fresh 52 Week Highs and Lows
Wednesday, August 3, 2011 - 1:05am | 5002Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to...